BAUSCH HEALTH COMPANIES INC/ CA0717341071 /
11/29/2023 4:30:10 PM | Chg. +0.31 | Volume | Bid4:30:10 PM | Ask4:30:10 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
9.62CAD | +3.33% | 64,420 Turnover: 609,630.50 |
9.62Bid Size: 600 | 9.63Ask Size: 200 | 3.49 bill.CAD | - | - |
Newsfile Corp
8/14
BHC Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Bausch Health Companies Inc. (...
Newsfile Corp
8/6
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors to Secure Coun...
GlobeNewswire
3/29/2022
Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development
GlobeNewswire
3/7/2022
EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officer
GlobeNewswire
2/24/2022
Palette Life Sciences Enters Into an Agreement with Lantheus to Support the Promotion of PYLARIFY® (...
GlobeNewswire
2/24/2022
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
GlobeNewswire
2/23/2022
Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries
GlobeNewswire
2/10/2022
Lantheus Announces Presentation Featuring PYLARIFY® (Piflufolastat F18) at the 2022 ASCO GU Meeting
GlobeNewswire
2/10/2022
Lantheus Holdings to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on ...
GlobeNewswire
1/27/2022
Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabl...
GlobeNewswire
11/22/2021
Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) I...
GlobeNewswire
11/17/2021
Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targete...
GlobeNewswire
11/17/2021
Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe
GlobeNewswire
11/16/2021
Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference
GlobeNewswire
11/16/2021
Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy...
GlobeNewswire
11/4/2021
Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia